Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004917 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00004917 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group.
The verdict
NCT00004917, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may stimulate red blood cell production and treat anemia in patients with head and neck cancer. It is not yet known whether receiving radiation therapy with epoetin alfa is more effective than radiation therapy alone in treating anemic patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without epoetin alfa in treating anemic patients who have head and neck cancer.
Interventions
- DRUG cisplatin
- RADIATION radiation therapy
- BIOLOGICAL epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004917
The ClinicalTrials.gov registry entry for NCT00004917 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00004917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004917 about?
NCT00004917 is a clinical study titled "Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may stimulate red blood cell production and treat anemia in patients with head and neck cancer. It is not yet known whether receiving radiation therapy with epoetin alfa is more effective than radiation therapy ...
What is the current status of trial NCT00004917?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00004917?
The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004917?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.